Just a week after Getinge temporarily lost CE mark clearance in Europe for its Cardiosave intra-aortic balloon pumps, the FDA has handed down a Class I recall rating to the devices—the second such label this year.
The Alzheimer’s Drug Discovery Foundation, formed 25 years ago in honor of cosmetic business tycoon Estée Lauder, just received $200 million from the Lauder family—the nonprofit’s largest donation ever.
Swedish patient enrollment company Trialbee has inked a partnership with Savvy Cooperative, which describes itself as the first and only patient-owned public benefit co-op.
Try as Philips might to forge a path out of its two-year-long saga of a slew of respiratory device recalls—complete with a new CEO and a new head of the beleaguered connected care division—the company is facing yet another, linked to more than 62,000 of its ventilators.
NGM Bio’s webpage declares “We’re Hiring!” but a peek at the investor relations section of the biotech’s website tells a different—and sobering—story.
You wait months for a molecular glue degrader licensing deal, and then two come along at once. At the same moment that Merck & Co. revealed it’s signed up to explore the modality with Austria’s Proxygen, a similar announcement has been made by Incyte.
OncoSec Medical’s six-year pursuit of potentially pivotal data on its Keytruda combination has delivered a last-minute twist. After touting an 18.8% investigator-assessed response rate, the biotech has revealed that the final result per blinded independent central review (BICR) fell well short of the bar for success.
When setting up a brand-new biotech, founders have a host of roles to fill and salaries to set. To attract the best talent, compensation has to be just right.
Concept Life Sciences, a U.K.-based CRO, has been acquired by Limerston Capital for an undisclosed amount, marking the fourth life sciences platform deal for the investment firm.
Proxygen’s molecular glue ambitions are continuing to take shape as the Austrian biotech sticks together a third licensing deal in less than three years.